
Opinion|Videos|May 28, 2025
Preventive Strategies and Emerging Therapies for Bronchiectasis
Panelists discuss how preventing bronchiectasis exacerbations involves understanding a patient’s past exacerbation pattern, implementing comprehensive airway clearance, patient education, and early intervention.
Advertisement
Episodes in this series

Clinical Brief: Preventive Strategies for Bronchiectasis
Main Discussion Topics
- Past exacerbation patterns strongly predict future exacerbations.
- Patient education about early recognition of exacerbations is crucial.
- Understanding the consequences of exacerbations motivates prevention.
Key Points for Physicians
- Review detailed exacerbation history through patient interviews and pharmacy dispensing records.
- Implement and review bronchiectasis action plans at each visit.
- Educate patients about the following:
- Signs and symptoms of exacerbation
- Increasing airway clearance frequency during early exacerbation
- Importance of prompt notification and sputum submission
- Emphasize that exacerbations cause progressive airway damage (“time is lung”)
- Monitor for sarcopenia and nutritional issues, which can worsen outcomes.
Notable Insights
Beyond airway damage, the systemic effects of exacerbations (sarcopenia, nutritional deficits, increased frailty) can significantly impact long-term prognosis, particularly in older patients.
Clinical Significance
A proactive approach to bronchiectasis management emphasizing exacerbation prevention and early intervention can significantly reduce progressive airway damage and systemic complications.
Advertisement
Related to this article

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5

